Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for kids ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Novo Nordisk A/S (NVO) has turned into one of the most valuable pharma companies in the world thanks to its success with weight loss drug Wegovy. But growth has recently slowed down, and the ...

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases, utilizing NanoVation's lipid nanoparticle technology. The deal includes research ...